Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 19/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4094990 | 1.00 | P2RX7 (0.63) | P2RX7 | |
| SCHEMBL4094993 | 1.00 | P2RX7 (0.63) | P2RX7 | |
| SCHEMBL4129931 | 0.87 | P2RX7 (0.71) | P2RX7 | |
| SCHEMBL14199708 | 0.84 | P2RX7 (0.67) | P2RX7 | |
| SCHEMBL5336494 | 0.81 | P2RX7 (0.78) | P2RX7 | |
| SCHEMBL7555635 | 0.81 | P2RX7 (0.72) | P2RX7 | |
| SCHEMBL4129972 | 0.80 | P2RX7 (0.74) | P2RX7 | |
| SCHEMBL4129949 | 0.79 | P2RX7 (0.69) | P2RX7 | |
| SCHEMBL4129123 | 0.79 | P2RX7 (0.86) | P2RX7 | |
| SCHEMBL4129203 | 0.79 | P2RX7 (0.71) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2059497-A1 | PROCESS FOR PREPARING N-METHYLADAMANTYL DERIVATIVES BY A PALLADIUM CATALYSED COUPLING REACTION FOLLOWED BY REDUCTIVE AMINATION | AstraZeneca AB (SE) | 2009-05-20 | — | — | EP | disclosed |
| US-20080081928-A1 | reacting 2-chloro-5-iodo-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-benzamide with allyl alcohol in the presence of a palladium catalyst and a tertiary amine base, to form 2-chloro-5-(3-oxopropyl)-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-benzamide; chemical intermediates for drugs | ASTRAZENECA AB (SE) | 2008-04-03 | — | — | US | disclosed |
| WO-2008030160-A1 | PROCESS FOR PREPARING N-METHYLADAMANTYL DERIVATIVES BY A PALLADIUM CATALYSED COUPLING REACTION FOLLOWED BY REDUCTIVE AMINATION | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081928-A1 | reacting 2-chloro-5-iodo-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-benzamide with allyl alcohol in the presence of a palladium catalyst and a tertiary amine base, to form 2-chloro-5-(3-oxopropyl)-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-benzamide; chemical intermediates for drugs | ADH1A, ADH1C, ADH5 | P2RX7 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.